Prelude Therapeutics (PRLD) 10-Q2024 Q1 Quarterly report

Filed: 7 May 24, 7:20am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ADC, agent, AML, arrangement, avoid, began, bill, Biosecure, borrowing, chief, China, Chinese, civil, collaboration, collaborative, collateralized, composition, Congressional, Corrupt, corruption, corruptive, criminal, customer, description, discount, discourage, docetaxel, dollar, exposed, family, FCPA, good, implemented, improper, jointly, led, length, leukemia, liable, mainland, maker, military, mutant, nil, NSCLC, Open, optimal, partner, placement, point, professional, prohibit, proportion, regularly, renegotiated, retaliatory, ROU, royalty, scrutiny, segment, shelf, single, statute, steady, step, subscription, successor, Taiwan, Taiwanese, tension, therapy, Topic, unauthorized

Removed: acted, amendment, amortization, August, Bank, beneficial, BofA, concentration, convey, declared, division, earliest, economy, existence, experience, experienced, Goldman, IPO, July, labor, life, liquidity, located, manageable, mitigate, Morgan, nanomolar, October, opt, pandemic, planned, Plaza, possession, predict, project, rapidly, registered, September, shipping, Silicon, spanning, Stanley, strive, structure, supplemented, supply, thousand, uncertainty, underway, underwriting, Valley, weakening

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRLD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bryant Lim, Chief Financial Officer of Prelude Therapeutics Incorporated (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 7, 2024	By:	/s/ Bryant Lim
		Byrant Lim
		Interim Chief Financial Officer (Principal Accounting and Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.